Verastem Inc (VSTM) Stock Price, Quote & News

Company Profile

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 292 4200

Website: www.verastem.com

Address:

117 Kendrick Street, Suite 500, Needham, United States

Crivit Sep. 3 at 4:18 AM

$VSTM also a benefit for $NVAX

0 · Reply

alaskawing Sep. 3 at 4:08 AM

$VSTM Although it didn't close there, VSTM Posted $9.55 today, a new 52 week high. This is a good sign and should attract those ALGOs and humans watching the 52 week high lists. Bullish as hell IMO.

0 · Reply

UWilDue0 Sep. 2 at 7:47 PM

$VSTM going to feel good when this is over $10 permanently

0 · Reply

sweddle Sep. 2 at 7:30 PM

$VSTM that 200SMA on the weekly is a tough nut to crack.

0 · Reply

alaskawing Sep. 2 at 4:42 PM

$VSTM XBI is rocking today....I believe there might be a rotation into Health/Biotech where VSTM will continue its momentum.

0 · Reply

jacksparo Sep. 2 at 4:12 PM

It is an overall red market today I am not too worried $SLS $AKBA $OMEX $BTBT $VSTM

2 · Reply

jacksparo Sep. 2 at 2:24 PM

Steady and strong opening for September in $GEVO $SLS $VSTM $PGEN So far.

0 · Reply

Consti22 Sep. 2 at 2:13 PM

$VSTM 💪🍀

0 · Reply

boston_drew Sep. 2 at 2:02 PM

$VSTM Verastem has 981.46 million in tax losses worth about $200M to a company like Amgen - could be a nice sweetner

1 · Reply

ChesterKaita Sep. 2 at 1:56 PM

$VSTM

0 · Reply

Verastem Oncology to Present at Upcoming Investor Conferences

Aug 13, 2025, 4:29 PM EDT - 20 days ago

Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer

Aug 8, 2025, 8:55 PM EDT - 25 days ago

Verastem, Inc. (VSTM) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 26 days ago

Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

Jul 29, 2025, 7:30 AM EDT - 5 weeks ago

Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 24, 2025, 7:30 AM EDT - 5 weeks ago

Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer

Jul 16, 2025, 8:22 AM EDT - 6 weeks ago

Verastem: The Market Is Ignoring The Progress

Jul 11, 2025, 4:12 PM EDT - 7 weeks ago

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology

Jul 8, 2025, 7:30 AM EDT - 2 months ago

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 30, 2025, 4:02 PM EDT - 2 months ago

Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer

Jun 26, 2025, 11:16 AM EDT - 2 months ago

Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers

Jun 24, 2025, 4:02 PM EDT - 2 months ago

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

Jun 2, 2025, 9:40 AM EDT - 3 months ago

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

May 28, 2025, 7:30 AM EDT - 3 months ago

Verastem Oncology to Present at the Jefferies Global Healthcare Conference

May 22, 2025, 5:01 PM EDT - 3 months ago

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma

May 20, 2025, 8:30 AM EDT - 3 months ago

Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment

TEM

May 13, 2025, 4:34 PM EDT - 4 months ago

Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates

May 8, 2025, 1:17 PM EDT - 4 months ago

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

May 8, 2025, 12:23 PM EDT - 4 months ago

U.S. FDA approves Verastem's cancer therapy

Apr 25, 2025, 9:00 AM EDT - 4 months ago

Verastem Oncology Announces $75 million Private Placement

Apr 23, 2025, 4:05 PM EDT - 4 months ago

Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors

Apr 10, 2025, 2:35 PM EDT - 5 months ago

Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination

Mar 25, 2025, 4:35 PM EDT - 5 months ago

Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025

Mar 20, 2025, 4:01 PM EDT - 5 months ago

Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

Feb 20, 2025, 4:05 PM EST - 6 months ago

Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Jan 29, 2025, 7:30 AM EST - 7 months ago

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference

Jan 23, 2025, 7:30 AM EST - 7 months ago

Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

Jan 15, 2025, 7:30 AM EST - 8 months ago

Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

Jan 14, 2025, 7:30 AM EST - 8 months ago

Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China

Jan 13, 2025, 7:30 AM EST - 8 months ago

Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025

Jan 3, 2025, 11:56 AM EST - 8 months ago

Verastem: Planning The PDUFA Run-Up

Jan 2, 2025, 11:39 AM EST - 8 months ago

Verastem: BLA Acceptance Puts Key Goals In Sight

Dec 31, 2024, 10:59 AM EST - 8 months ago

Why Is Cancer-Focused Verastem Oncology Stock Trading Higher On Tuesday?

Dec 30, 2024, 4:30 PM EST - 8 months ago

Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Dec 18, 2024, 7:30 AM EST - 9 months ago

Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Nov 27, 2024, 1:28 PM EST - 9 months ago

Verastem: Preparing For Upcoming Catalysts

Nov 26, 2024, 7:00 AM EST - 10 months ago

Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference

Nov 6, 2024, 4:05 PM EST - 10 months ago

Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Oct 31, 2024, 4:01 PM EDT - 10 months ago

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Oct 31, 2024, 7:30 AM EDT - 10 months ago

Verastem Oncology to Participate in Upcoming Investor Conferences

Oct 17, 2024, 1:00 AM EDT - 11 months ago

Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting

Oct 9, 2024, 6:00 AM EDT - 11 months ago

Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting

Sep 10, 2024, 4:05 PM EDT - 1 year ago

Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference

Sep 10, 2024, 7:30 AM EDT - 1 year ago

Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting

Sep 5, 2024, 11:21 PM EDT - 1 year ago

Verastem's Path To FDA Approval: High-Risk, High-Reward Oncology Opportunity

Sep 3, 2024, 7:30 AM EDT - 1 year ago

Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates

Jul 29, 2024, 4:01 PM EDT - 1 year ago

Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer

Jul 23, 2024, 11:20 PM EDT - 1 year ago

Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants

Jul 23, 2024, 4:05 PM EDT - 1 year ago

Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants

Crivit Sep. 3 at 4:18 AM

$VSTM also a benefit for $NVAX

0 · Reply

alaskawing Sep. 3 at 4:08 AM

$VSTM Although it didn't close there, VSTM Posted $9.55 today, a new 52 week high. This is a good sign and should attract those ALGOs and humans watching the 52 week high lists. Bullish as hell IMO.

0 · Reply

UWilDue0 Sep. 2 at 7:47 PM

$VSTM going to feel good when this is over $10 permanently

0 · Reply

sweddle Sep. 2 at 7:30 PM

$VSTM that 200SMA on the weekly is a tough nut to crack.

0 · Reply

alaskawing Sep. 2 at 4:42 PM

$VSTM XBI is rocking today....I believe there might be a rotation into Health/Biotech where VSTM will continue its momentum.

0 · Reply

jacksparo Sep. 2 at 4:12 PM

It is an overall red market today I am not too worried $SLS $AKBA $OMEX $BTBT $VSTM

2 · Reply

jacksparo Sep. 2 at 2:24 PM

Steady and strong opening for September in $GEVO $SLS $VSTM $PGEN So far.

0 · Reply

Consti22 Sep. 2 at 2:13 PM

$VSTM 💪🍀

0 · Reply

boston_drew Sep. 2 at 2:02 PM

$VSTM Verastem has 981.46 million in tax losses worth about $200M to a company like Amgen - could be a nice sweetner

1 · Reply

ChesterKaita Sep. 2 at 1:56 PM

$VSTM

0 · Reply

AUgold Sep. 2 at 1:41 PM

$VSTM Back to days of double digits soon. Long 🐂

0 · Reply

Geraldgenofranco1975 Aug. 31 at 8:38 PM

$SLS $VSTM $MBOT $AKBA Let us go Jack do not forget $ICU

0 · Reply

jacksparo Aug. 30 at 9:40 PM

$SLS I don’t like long weekends usually 😁 but I will use the time to dig deep into all the possibilities here. I think September and October both so important month for it. $VSTM I think we are matching higher here 📈✅! $MBOT Important time in this one I traded it with good profits but I am keeping it in my closet watch list as it is getting closer to the FDA decision ✅! $AKBA I am holding strong for the long term opportunity 📈✅!

1 · Reply

250STXTraders Aug. 30 at 1:34 PM

$VSTM how can you begin to estimate a reasonable buyout price for the stock.?

1 · Reply

Robertbuote Aug. 30 at 12:52 PM

$VSTM Hope is not a strategy and past is not prologue. Look forward not backward for the future of this stock. Smooth launch of AVMAPKI FAKZYNJA Co-Pack will generate cash flow positive balance sheet by early next year. Minimal dilution going forward. Trials will be funded from revenue. VS-7375 and other pipeline assets will add to share price/market cap. And the shorts will eventually capitulate and cover, further supporting share price. The future is bright. Unless you need the money now, hold for mid double digits.

0 · Reply

Consti22 Aug. 30 at 9:07 AM

$VSTM What do you think the price per share would be in the event of a takeover?

6 · Reply

jerzbondon Aug. 30 at 3:36 AM

$VSTM I am looking at a 13-year chart of VSTM. I hope that the current uptrend will be permanent one to the bright future of this company. I hope it will break the pattern of a few temporary uptrends we have experienced over the past 13 years.

0 · Reply

NIJO89 Aug. 29 at 11:14 PM

$VSTM Estimation of revenue and patient population growth for VSTM LGSOC mution. Not taken into account quarterly fluctuations and future possible LGSOC Wildtype indication inclusion in NCCN guideline or FDA approval nor off-label prescriptions or other indications approved for treatment of Pancreatic etc.

1 · Reply

Teddy313 Aug. 29 at 8:05 PM

$VSTM OK nice close in a sloppy market, Now I'm watching to see if VSTM gets bought out first or TRVI does. Loaded with both for the big payday. It's going to happen it's in the wind....

0 · Reply

Teddy313 Aug. 29 at 7:59 PM

$VSTM Very funny stock goin up going into the close before 3 day weekend, we all want to own the stock for the big payday....Buyout any time now maybe Tuesday....I have had 3 low price bios that got bought out made up for all my losers...This is my opinion only and I really believe a large Pharma will want VSTMs drugs. Have a great weekend longs...Watch CNBC 7 AM eastern time Tuesday. IMO...It happens every once in a while for me...I'm over due now...

0 · Reply

DreyOfAllTrades Aug. 29 at 3:18 PM

$ETHZ $DVLT $STEM $VSTM $EQ ive seen this movie before. Sold everything till market goes back green

0 · Reply

Stoltz13 Aug. 29 at 11:56 AM

$VSTM gonna be new highs soon

0 · Reply

Market Cap	569.29M
Revenue (ttm)	10.00M
Net Income (ttm)	-130.64M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,306.40%
Debt to Equity Ratio	2.06

Volume	1,814,400
Avg Vol	2,713,842
Day's Range	N/A - N/A
Shares Out	61.55M
Stochastic %K	84%
Beta	0.92
Analysts	Strong Sell
Price Target	$15.50